Protective and Pathogenic Responses to Chikungunya Virus Infection

Current Tropical Medicine Reports

Volumn 2, Issue 1, 2015, Pages 13-21

  Long, Kristin M ^a   Heise, Mark T ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Alphavirus; Chikungunya virus; Immunopathology; Vaccine

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON RECEPTOR; INTERFERON; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR; VIRUS VACCINE;

ADAPTIVE IMMUNITY; APOPTOSIS; AUTOPHAGY; B LYMPHOCYTE; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINE PRODUCTION; VIRAL CLEARANCE; VIRUS CELL INTERACTION;

EID: 84932646657     PISSN: None     EISSN: 21963045     Source Type: Journal    
DOI: 10.1007/s40475-015-0037-z     Document Type: Review

References (113)

1. Suhrbier A, La Linn M. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol. 2004;16(4):374–9.
2. Schuffenecker I et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 2006;3(7):e263.
3. Vazeille M et al. Chikungunya: a risk for Mediterranean countries? Acta Trop. 2008;105(2):200–2.
4. Vazeille M et al. Two Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito Aedes albopictus. PLoS One. 2007;2(11):e1168.
5. Tsetsarkin KA et al. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. 2007;3(12):e201.
6. Diallo M et al. Vectors of Chikungunya virus in Senegal: current data and transmission cycles. Am J Trop Med Hyg. 1999;60(2):281–6.
7. Delatte H et al. Geographic distribution and developmental sites of Aedes albopictus (Diptera: Culicidae) during a Chikungunya epidemic event. Vector Borne Zoonotic Dis. 2008;8(1):25–34.
8. Simon, F., H. Tolou, and P. Jeandel, [The unexpected Chikungunya outbreak]. Rev Med Interne, 2006. 27(6): p. 437–41.
9. Sergon K et al. Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya, October 2004. Am J Trop Med Hyg. 2008;78(2):333–7.
10. Sergon K et al. Seroprevalence of Chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop Med Hyg. 2007;76(6):1189–93.
11. Laras K et al. Tracking the re-emergence of epidemic chikungunya virus in Indonesia. Trans R Soc Trop Med Hyg. 2005;99(2):128–41.
12. Pialoux G et al. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis. 2007;7(5):319–27.
13. Rezza G et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet. 2007;370(9602):1840–6.
14. Beltrame A et al. Imported Chikungunya Infection Italy. Emerg Infect Dis. 2007;13(8):1264–6.
15. Angelini P et al. Chikungunya epidemic outbreak in Emilia-Romagna (Italy) during summer 2007. Parassitologia. 2008;50(1–2):97–8.
16. Angelini, R., et al., An outbreak of chikungunya fever in the province of Ravenna, Italy. Euro Surveill, 2007. 12(9): p. E070906 1.
17. Cassadou, S., et al., Emergence of chikungunya fever on the French side of Saint Martin island, October to December 2013. Euro Surveill, 2014. 19(13).
18. Leparc-Goffart I et al. Chikungunya in the Americas. Lancet. 2014;383(9916):514.
19. Van Bortel, W., et al., Chikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for Europe. Euro Surveill, 2014. 19(13).
20. Centers for Disease Control and Prevention. Chikungunya in the Americas. October 21, 2014 [cited 2014 October 27, 2014].
21. Centers for Disease Control and Prevention. Chikungunya virus in the United States. October 21, 2014 [cited 2014 October 27, 2014]; Available from: http://www.cdc.gov/chikungunya/geo/united-states.html.
22. Simon F et al. Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases. Medicine (Baltimore). 2007;86(3):123–37.
23. Sissoko D et al. Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl Trop Dis. 2009;3(3):e389.
24. Mourya DT, Mishra AC. Chikungunya fever. Lancet. 2006;368(9531):186–7.
25. Yazdani R, Kaushik VV. Chikungunya fever. Rheumatology (Oxford). 2007;46(7):1214–5. author reply 1215.
26. Fourie ED, Morrison JG. Rheumatoid arthritic syndrome after chikungunya fever. S Afr Med J. 1979;56(4):130–2.
27. Kennedy AC, Fleming J, Solomon L. Chikungunya viral arthropathy: a clinical description. J Rheumatol. 1980;7(2):231–6.
28. Brighton SW, Simson IW. A destructive arthropathy following Chikungunya virus arthritis—a possible association. Clin Rheumatol. 1984;3(2):253–8.
29. Manimunda SP et al. Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging. Trans R Soc Trop Med Hyg. 2010;104(6):392–9.
30. Soumahoro MK et al. Impact of Chikungunya virus infection on health status and quality of life: a retrospective cohort study. PLoS One. 2009;4(11):e7800.
31. Economopoulou A et al. Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005–2006 outbreak on Reunion. Epidemiol Infect. 2009;137(4):534–41.
32. Josseran L et al. Chikungunya disease outbreak Reunion Island. Emerg Infect Dis. 2006;12(12):1994–5.
33. Chua HH et al. A fatal case of chikungunya virus infection with liver involvement. Med J Malaysia. 2010;65(1):83–4.
34. Rampal M. Neurological complications in chikungunya fever. J Assoc Physicians India. 2007;55:765–9.
35. Rampal M. Hypokalemic paralysis following chikungunya fever. J Assoc Physicians India. 2007;55:598.
36. Wielanek AC et al. Guillain-Barre syndrome complicating a chikungunya virus infection. Neurology. 2007;69(22):2105–7.
37. Poo YS et al. CCR2 Deficiency Promotes Exacerbated Chronic Erosive Neutrophil-Dominated Chikungunya Virus Arthritis. J Virol. 2014. This study illustrated that complex role that specific chemokine signaling pathways play in the pathogenesis of CHIKV, which has potential implications for therapeutic development.
38. Hoarau JJ et al. Identical strength of the T cell responses against E2, nsP1 and capsid CHIKV proteins in recovered and chronic patients after the epidemics of 2005–2006 in La Reunion Island. PLoS One. 2013;8(12):e84695.
39. Hawman DW et al. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J Virol. 2013;87(24):13878–88.
40. Dupuis-Maguiraga L et al. Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia. PLoS Negl Trop Dis. 2012;6(3):e1446.
41. Stoermer KA et al. Genetic ablation of arginase 1 in macrophages and neutrophils enhances clearance of an arthritogenic alphavirus. J Immunol. 2012;189(8):4047–59. This study provides evidence suggesting that M2-like macrophages impact alphavirus clearance from infected tissues and the resolution of alphavirus-induced disease.
42. Sourisseau M et al. Characterization of reemerging chikungunya virus. PLoS Pathog. 2007;3(6):e89.
43. Dhanwani R et al. Characterization of chikungunya virus infection in human neuroblastoma SH-SY5Y cells: role of apoptosis in neuronal cell death. Virus Res. 2012;163(2):563–72.
44. Wikan N et al. Chikungunya virus infection of cell lines: analysis of the East, Central and South African lineage. PLoS One. 2012;7(1):e31102.
45. Puttamallesh VN et al. Proteomic profiling of serum samples from chikungunya-infected patients provides insights into host response. Clin Proteomics. 2013;10(1):14.
46. Dhanwani R et al. Differential proteome analysis of Chikungunya virus-infected new-born mice tissues reveal implication of stress, inflammatory and apoptotic pathways in disease pathogenesis. Proteomics. 2011;11(10):1936–51.
47. Bourai M et al. Mapping of Chikungunya virus interactions with host proteins identified nsP2 as a highly connected viral component. J Virol. 2012;86(6):3121–34.
48. Garmashova N et al. The Old World and New World alphaviruses use different virus-specific proteins for induction of transcriptional shutoff. J Virol. 2007;81(5):2472–84.
49. Toribio R, Ventoso I. Inhibition of host translation by virus infection in vivo. Proc Natl Acad Sci USA. 2010;107(21):9837–42.
50. Levine B et al. Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature. 1993;361(6414):739–42.
51. Griffin DE, Hardwick JM. Regulators of apoptosis on the road to persistent alphavirus infection. Annu Rev Microbiol. 1997;51:565–92.
52. Chen YB et al. Alternate functions of viral regulators of cell death. Cell Death Differ. 2006;13(8):1318–24.
53. Krejbich-Trotot P et al. Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses. FASEB J. 2011;25(1):314–25.
54. Cruz DJ et al. Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library. PLoS Negl Trop Dis. 2013;7(10):e2471.
55. Eng KE et al. Accumulation of autophagosomes in Semliki Forest virus-infected cells is dependent on expression of the viral glycoproteins. J Virol. 2012;86(10):5674–85.
56. Orvedahl A et al. Autophagy protects against Sindbis virus infection of the central nervous system. Cell Host Microbe. 2010;7(2):115–27.
57. Krejbich-Trotot P et al. Chikungunya triggers an autophagic process which promotes viral replication. Virol J. 2011;8:432.
58. Joubert PE et al. Chikungunya virus-induced autophagy delays caspase-dependent cell death. J Exp Med. 2012;209(5):1029–47.
59. Judith D et al. Species-specific impact of the autophagy machinery on Chikungunya virus infection. EMBO Rep. 2013;14(6):534–44. This study demonstrates that interactions between the human autophagy receptor NDP52 and the CHIKV nsP2 protein have a proviral effect by enhancing viral replication. Importantly, this effect is species specific, in that mouse NDP52 protein does not interact with CHIKV, suggesting that NSP52 may be a host range factor.
60. Rathore AP et al. Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo. Antiviral Res. 2014;103:7–16.
61. Das I et al. Heat shock protein 90 positively regulates Chikungunya virus replication by stabilizing viral non-structural protein nsP2 during infection. PLoS One. 2014;9(6):e100531.
62. Paingankar MS, Arankalle VA. Identification of chikungunya virus interacting proteins in mammalian cells. J Biosci. 2014;39(3):389–99.
63. Van Den Bossche, D., et al., Chikungunya virus and West Nile virus infections imported into Belgium, 2007–2012. Epidemiol Infect, 2014: p. 1–10.
64. Long KM et al. Dendritic cell immunoreceptor regulates Chikungunya virus pathogenesis in mice. J Virol. 2013;87(10):5697–706.
65. Wauquier N et al. The acute phase of Chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. J Infect Dis. 2011;204(1):115–23.
66. Couderc T et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog. 2008;4(2):e29.
67. Schilte C et al. Type I IFN controls chikungunya virus via its action on nonhematopoietic cells. J Exp Med. 2010;207(2):429–42.
68. White LK et al. Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff. J Virol. 2011;85(1):606–20.
69. Shabman RS et al. Differential induction of type I interferon responses in myeloid dendritic cells by mosquito and mammalian-cell-derived alphaviruses. J Virol. 2007;81(1):237–47.
70. Ryman KD et al. Sindbis virus translation is inhibited by a PKR/RNase L-independent effector induced by alpha/beta interferon priming of dendritic cells. J Virol. 2005;79(3):1487–99.
71. Schoggins JW et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011;472(7344):481–5.
72. Kam YW et al. Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. J Virol. 2012;86(23):13005–15.
73. Werneke SW et al. ISG15 is critical in the control of Chikungunya virus infection independent of UbE1L mediated conjugation. PLoS Pathog. 2011;7(10):e1002322.
74. Jones PH et al. BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1). Virology. 2013;438(1):37–49.
75. Mahauad-Fernandez, W.D., P.H. Jones, and C.M. Okeoma, Critical role for BST-2 in acute Chikungunya virus infection. J Gen Virol, 2014.
76. Gardner CL et al. Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate. Virology. 2012;425(2):103–12.
77. Teng TS et al. Viperin restricts chikungunya virus replication and pathology. J Clin Invest. 2012;122(12):4447–60. References 71–77 demonstrate that multiple distinct interferon stimulated genes exhibit antiviral activity against CHIKV, illustrating complexity of the host innate immune effectors that contribute to CHIKV control.
78. Gardner J et al. Chikungunya virus arthritis in adult wild-type mice. J Virol. 2010;84(16):8021–32.
79. Heise MT, Simpson DA, Johnston RE. Sindbis-group alphavirus replication in periosteum and endosteum of long bones in adult mice. J Virol. 2000;74(19):9294–9.
80. Morrison TE et al. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J Virol. 2006;80(2):737–49.
81. Morrison TE et al. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am J Pathol. 2011;178(1):32–40. This study demonstrated that CHIKV RNA persists within joints, but not other tissues, in a mouse model of CHIKV-induced arthritis.
82. Labadie K et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest. 2010;120(3):894–906.
83. Brandstadter JD, Yang Y. Natural killer cell responses to viral infection. J Innate Immun. 2011;3(3):274–9.
84. Rulli NE et al. Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis. J Infect Dis. 2011;204(7):1026–30.
85. Poo YS et al. CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritis. J Virol. 2014;88(12):6862–72.
86. Ruffell D et al. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc Natl Acad Sci USA. 2009;106(41):17475–80.
87. Loke P et al. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol. 2007;179(6):3926–36.
88. Hoarau JJ et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol. 2010;184(10):5914–27. This study found that chronic CHIKV-induced arthralgia was more prevalent in individuals age 60 or older, and provides evidence CHIKV can persist over the long term within the joints of persons suffering from chronic CHIKV-induced joint disease.
89. Trifilo MJ et al. CXC chemokine ligand 10 controls viral infection in the central nervous system: evidence for a role in innate immune response through recruitment and activation of natural killer cells. J Virol. 2004;78(2):585–94.
90. Ng LF et al. IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity. PLoS One. 2009;4(1):e4261.
91. Petitdemange C et al. Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog. 2011;7(9):e1002268.
92. Gardner JP et al. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol. 2000;74(24):11849–57.
93. Nishimoto KP et al. Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunol. 2007;20(1):88–104.
94. Her Z et al. Active infection of human blood monocytes by Chikungunya virus triggers an innate immune response. J Immunol. 2010;184(10):5903–13.
95. Teo TH et al. A pathogenic role for CD4+ T cells during chikungunya virus infection in mice. J Immunol. 2013;190(1):259–69. This study demonstrates that CD4 T cells contribute to the development of foot sweling in a mouse model of CHIKV-induced arthritis.
96. Borgherini G et al. Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. Clin Infect Dis. 2007;44(11):1401–7.
97. Lum FM et al. An essential role of antibodies in the control of Chikungunya virus infection. J Immunol. 2013;190(12):6295–302.
98. Couderc T et al. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis. 2009;200(4):516–23.
99. Pal P et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog. 2013;9(4):e1003312.
100. Vijayakumar KP et al. Clinical profile of chikungunya patients during the epidemic of 2007 in Kerala. India J Glob Infect Dis. 2011;3(3):221–6.
101. Krishnamoorthy K et al. Burden of chikungunya in India: estimates of disability adjusted life years (DALY) lost in 2006 epidemic. J Vector Borne Dis. 2009;46(1):26–35.
102. Levitt NH et al. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine. 1986;4(3):157–62.
103. Edelman R et al. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg. 2000;62(6):681–5.
104. Gorchakov R et al. Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J Virol. 2012;86(11):6084–96.
105. Hallengard D et al. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J Virol. 2014;88(5):2858–66.
106. Plante K et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog. 2011;7(7):e1002142.
107. Roy CJ et al. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis. 2014;209(12):1891–9.
108. Noranate N et al. Characterization of chikungunya virus-like particles. PLoS One. 2014;9(9):e108169.
109. Akahata W et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010;16(3):334–8.
110. Chang, L.J., et al., Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet, 2014
111. Garcia-Arriaza J et al. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol. 2014;88(6):3527–47.
112. van den Doel P et al. Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of chikungunya virus protects AG129 mice against lethal challenge. PLoS Negl Trop Dis. 2014;8(9):e3101.
113. Weger-Lucarelli J et al. A novel MVA vectored chikungunya virus vaccine elicits protective immunity in mice. PLoS Negl Trop Dis. 2014;8(7):e2970.